Financings Of The Fortnight: Boehringer's New Corporate Venture Fund Good News For Biotech
This article was originally published in The Pink Sheet Daily
Executive Summary
Achaogen raises a $56 million Series C to support next-generation antibiotic program, while Somaxon's follow-on public offering nets $52.8 million.
You may also be interested in...
Corporate Venture Strikes Again: Biocartis Lands €30 million--And A Partnership
The two deals help pave a path toward commercialization for the privately-held Swiss molecular diagnostics player.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.